WORLD · VERIFIED DEVELOPMENT
MSF Launches Ebola Vaccine Study Among DRC Frontline Workers
WHY IT MATTERS
The BRAVO study will produce real‑world evidence on ERVEBO’s effectiveness against Bundibugyo, guiding future vaccine strategies and potentially lowering severe cases among high‑risk health workers.
What happened
Médecins Sans Frontières (MSF) and its research arm Epicentre have begun the BRAVO study in the Democratic Republic of Congo, enrolling up to 20,000 frontline health workers in Ituri and North Kivu provinces. The nine‑to‑twelve‑month trial will administer the ERVEBO vaccine, the only Ebola vaccine currently available at scale, and then follow participants for at least six months.
The outbreak, driven by the Bundibugyo strain, has no dedicated vaccine or treatment, and ERVEBO was originally licensed for the Zaire strain. Early data suggest it may offer partial protection against Bundibugyo, but this must be confirmed scientifically.
The study is coordinated with the Ministry of Health, Africa CDC, and the Congolese National Institute for Biomedical Research, and participation is voluntary. Vaccination is an additional safeguard and does not replace standard infection‑control practices.
PRIMARY SOURCES
DR Congo: MSF launches Ebola disease vaccination study among DRC frontline workers
ReliefWeb / original provider · Médecins Sans Frontières · ReliefWeb aggregation; original provider terms apply; link and attribution to the named source required